Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 178 of 178 drug-target rows in SSL view, for TSG = KDM6A.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
olaparib KDM6A PARP1 1
sunitinib KDM6A MET 5
crizotinib KDM6A MET 7
trastuzumab emtansine KDM6A ERBB2 7
tucatinib KDM6A ERBB2 7
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KDM6A MET 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KDM6A SMO 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KDM6A ERBB2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KDM6A CSK 3
afatinib KDM6A ERBB2 3
mrtx849, pembrolizumab, cetuximab, afatinib KDM6A ERBB2 3
cabozantinib KDM6A MET 7
lapatinib KDM6A ERBB2 7
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel KDM6A MET 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel KDM6A ERBB2 2
alvocidib, paclitaxel KDM6A CDK9 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment KDM6A CSK 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib KDM6A MET 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab KDM6A ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib KDM6A ERBB2 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study KDM6A HDAC2 2
motexafin gadolinium, radiation therapy KDM6A RRM2 2
pembrolizumab, guadecitabine, mocetinostat KDM6A HDAC2 2
pembrolizumab, sonidegib KDM6A SMO 2
pharmacological study, romidepsin KDM6A HDAC2 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies KDM6A ERBB2 2
tivantinib KDM6A MET 2
trastuzumab KDM6A ERBB2 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy KDM6A ERBB2 2
trastuzumab, tipifarnib KDM6A ERBB2 2
romidepsin KDM6A HDAC2 7
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks KDM6A ERBB2 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat KDM6A HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat KDM6A HDAC2 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide KDM6A RRM2 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy KDM6A ERBB2 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy KDM6A HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid KDM6A HDAC2 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging KDM6A ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib KDM6A ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib KDM6A CSK 1
afatinib, docetaxel, radiation therapy KDM6A ERBB2 1
afatinib, gefitinib KDM6A ERBB2 1
afatinib, irinotecan KDM6A ERBB2 1
alvocidib, docetaxel KDM6A CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis KDM6A CDK9 1
amivantamab KDM6A MET 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib KDM6A SMO 1
atezolizumab, cabozantinib KDM6A MET 1
atezolizumab, tivozanib KDM6A MET 1
atorvastatin, temozolomide, radiotherapy KDM6A HDAC2 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab KDM6A HDAC2 1
bevacizumab, dasatinib, placebo KDM6A CSK 1
bevacizumab, temozolomide, vorinostat KDM6A HDAC2 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib KDM6A MET 1
biopsy, biospecimen collection, crizotinib, radiologic examination KDM6A MET 1
biopsy, biospecimen collection, echocardiography, pertuzumab, radiologic examination, trastuzumab KDM6A ERBB2 1
biopsy, biospecimen collection, echocardiography, radionuclide imaging, vismodegib KDM6A SMO 1
cabozantinib, durvalumab, tremelimumab KDM6A MET 1
cabozantinib, nivolumab KDM6A MET 1
cabozantinib, pembrolizumab KDM6A MET 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab KDM6A ERBB2 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor KDM6A HDAC2 1
carboplatin, laboratory biomarker analysis, paclitaxel, quality-of-life assessment, radiation therapy, therapeutic conventional surgery, trastuzumab KDM6A ERBB2 1
cetuximab, trastuzumab KDM6A ERBB2 1
chemotherapy, cladribine, radiation therapy KDM6A RRM2 1
cisplatin, 5-fluorouracil or capecitabine, trastuzumab, pertuzumab, gastrectomy KDM6A ERBB2 1
conventional surgery, 3-dimensional conformal radiation therapy, stereotactic radiosurgery, motexafin gadolinium, magnetic resonance imaging, spectroscopy KDM6A RRM2 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride KDM6A CSK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method KDM6A CSK 1
dasatinib, laboratory biomarker analysis, physiologic testing KDM6A CSK 1
dasatinib, mfolfox6 KDM6A CSK 1
dasatinib, pharmacological study KDM6A CSK 1
dasatinib, temozolomide, placebo, radiation therapy KDM6A CSK 1
db-1310, trastuzumab, osimertinib KDM6A ERBB2 1
diagnostic laboratory biomarker analysis, erlotinib hydrochloride, gemcitabine hydrochloride, vismodegib KDM6A SMO 1
disitamab vedotin, tucatinib KDM6A ERBB2 1
docetaxel, leucovorin, fluorouracil, cisplatin, docetaxel, cisplatin, fluorouracil, neulasta, or neupogen, docetaxel, leukvorin, flurouracil, cisplatin, trastuzumab KDM6A ERBB2 1
docetaxel, oxaliplatin, capecitabine, trastuzumab KDM6A ERBB2 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) KDM6A PIK3R1 1
enzastaurin, lomustine KDM6A PIK3R1 1
enzastaurin, temozolomide, radiation therapy KDM6A PIK3R1 1
evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel KDM6A ERBB2 1
fluorouracil (5-fu), capecitabine, durvalumab, oxaliplatin, trastuzumab, trastuzumab deruxtecan, cisplatin, pembrolizumab, volrustomig, rilvegostomig KDM6A ERBB2 1
gemcitabine hydrochloride, hydrocortisone/placebo, vismodegib KDM6A SMO 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim KDM6A SMO 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff KDM6A HDAC2 1
gemcitabine, sunitinib KDM6A MET 1
imexon, gemcitabine KDM6A RRM2 1
irinotecan, cisplatin, simvastatin KDM6A HDAC2 1
ko-2806, cabozantinib, adagrasib KDM6A MET 1
laboratory biomarker analysis, lapatinib, lapatinib ditosylate, pharmacological study, therapeutic conventional surgery KDM6A ERBB2 1
laboratory biomarker analysis, pegfilgrastim, pharmacological study, tivantinib, topotecan hydrochloride KDM6A MET 1
laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat KDM6A HDAC2 1
lapatinib, chemoradiation, placebo KDM6A ERBB2 1
lapatinib, placebo KDM6A ERBB2 1
lapatinib, placebo, capecitabine, oxaliplatin KDM6A ERBB2 1
lonafarnib, temozolomide KDM6A FNTA 1
lonsurf, oxaliplatin, panitumumab, bevacizumab, trastuzumab, nivolumab KDM6A ERBB2 1
motexafin gadolinium KDM6A RRM2 1
motexafin gadolinium, magnetic resonance imaging, surgical procedure KDM6A RRM2 1
nal-iri, oxaliplatin, 5-fu, trastuzumab, pembrolizumab, nivolumab KDM6A ERBB2 1
nivolumab, cabozantinib KDM6A MET 1
oxaliplatin, leucovorin, 5 fluorouracil, trastuzumab, avelumab KDM6A ERBB2 1
palbociclib, afatinib KDM6A ERBB2 1
pazopanib, lapatinib KDM6A ERBB2 1
pembrolizumab, placebo, cisplatin, 5-fu, oxaliplatin, capecitabine, s-1, trastuzumab KDM6A ERBB2 1
pembrolizumab, trastuzumab, oxaliplatin, capecitabine KDM6A ERBB2 1
pembrolizumab, vorinostat, temozolomide, radiotherapy KDM6A HDAC2 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule KDM6A HDAC2 1
romidepsin, laboratory biomarker analysis KDM6A HDAC2 1
ryz101, everolimus, sunitinib, octreotide, lanreotide KDM6A MET 1
sorafenib tosylate, valproic acid, sildenafil citrate KDM6A HDAC2 1
sunitinib, placebo KDM6A MET 1
sunitinib, radiation KDM6A MET 1
sunitinib, sunitinib KDM6A MET 1
tesevatinib KDM6A ERBB2 1
tirelizumab, trastuzumab, docetaxel, s1, oxaliplatin KDM6A ERBB2 1
tivantinib, folfox KDM6A MET 1
tivozanib KDM6A MET 1
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry, adjuvant therapy, quality-of-life assessment KDM6A ERBB2 1
trastuzumab, pertuzumab, paclitaxel, carboplatin KDM6A ERBB2 1
trilaciclib KDM6A CDK9 1
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab KDM6A ERBB2 1
tucatinib, trastuzumab, ramucirumab, paclitaxel, tucatinib placebo, trastuzumab placebo KDM6A ERBB2 1
valproic acid KDM6A HDAC2 1
valproic acid, bevacizumab, radiation therapy KDM6A HDAC2 1
valproic acid, simvastatin 20mg, gemcitabine 1000 mg, nab paclitaxel, cisplatin, capecitabine KDM6A HDAC2 1
vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose f 18 KDM6A SMO 1
vismodegib, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study KDM6A SMO 1
vorinostat, bevacizumab KDM6A HDAC2 1
vorinostat, bevacizumab, irinotecan KDM6A HDAC2 1
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis KDM6A HDAC2 1
vorinostat, conventional surgery KDM6A HDAC2 1
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study KDM6A HDAC2 1
vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration KDM6A HDAC2 1
vorinostat, therapeutic conventional surgery, bortezomib KDM6A HDAC2 1
zanidatamab, tislelizumab, trastuzumab, capecitabine, oxaliplatin, cisplatin, 5-fluorouracil KDM6A ERBB2 1
zongertinib, trastuzumab deruxtecan, trastuzumab emtansine KDM6A ERBB2 1
afatinib dimaleate KDM6A ERBB2 7
belinostat KDM6A HDAC2 7
cabozantinib s-malate KDM6A MET 7
capmatinib KDM6A MET 7
capmatinib hydrochloride KDM6A MET 7
clofarabine KDM6A RRM2 7
gallium citrate KDM6A RRM2 7
gallium citrate ga 67 KDM6A RRM2 7
gallium nitrate KDM6A RRM2 7
gallium oxodotreotide KDM6A RRM2 7
gallium oxodotreotide ga-68 KDM6A RRM2 7
gemcitabine KDM6A RRM2 7
gemcitabine hydrochloride KDM6A RRM2 7
glasdegib KDM6A SMO 7
glasdegib maleate KDM6A SMO 7
hydroxyurea KDM6A RRM2 7
lanreotide KDM6A ERBB2 7
lanreotide acetate KDM6A ERBB2 7
lapatinib ditosylate KDM6A ERBB2 7
lonafarnib KDM6A FNTA 7
neratinib KDM6A ERBB2 7
neratinib maleate KDM6A ERBB2 7
niraparib KDM6A PARP1 7
niraparib tosylate KDM6A PARP1 7
panobinostat KDM6A HDAC2 7
panobinostat lactate KDM6A HDAC2 7
pertuzumab KDM6A ERBB2 7
rucaparib KDM6A PARP1 7
rucaparib camsylate KDM6A PARP1 7
sonidegib KDM6A SMO 7
sonidegib phosphate KDM6A SMO 7
talazoparib KDM6A PARP1 7
talazoparib tosylate KDM6A PARP1 7
tepotinib KDM6A MET 7
vandetanib KDM6A ERBB2 7
vismodegib KDM6A SMO 7
vorinostat KDM6A HDAC2 7
trastuzumab deruxtecan KDM6A ERBB2 4
dacomitinib KDM6A ERBB2 2
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.